This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
multiple-sclerosis
Multiple Sclerosis
Autoimmune demyelinating CNS disease mediated by autoreactive Th1/Th17 and CD8+ T cells attacking myelin; relapsing-remitting in 85% at onset. Natalizumab, ocrelizumab, and cladribine are high-efficacy DMTs; early aggressive therapy improves long-term disability outcomes.
Entry Metadata
| Field | Value |
|---|---|
| ID | multiple-sclerosis |
| Name | Multiple Sclerosis |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-1517. · PubMed 18970977
- Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910. · PubMed 16510744
- Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220. · PubMed 28002688